Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.
复制标题
2001年至2021年基于嵌合抗原受体的癌症免疫疗法的文献计量分析
DOI：
10.3389/fimmu.2022.822004
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
基于嵌合抗原受体（CAR）的免疫疗法在治疗造血恶性肿瘤和实体肿瘤方面显示出巨大的潜力。然而，多种障碍仍然阻碍了CAR-based免疫疗法在临床环境中的发展。在本研究中，我们旨在总结研究概况，突出该领域的前沿和趋势。在Web of Science Core Collection数据库中检索2001年至2021年发表的文献。提取并筛选了所有文件的完整记录和引用参考文献。使用CiteSpace、Microsoft Excel 2019、VOSviewer和R软件进行文献计量分析和可视化。共纳入5981篇文章和综述。近20年来，论文发表量和被引量呈上升趋势。《免疫学前沿》（Frontiers in Immunology）和《血液》（Blood）分别是产出最多和被共同引用最多的期刊。在全面的全球合作网络中，美国是组织和出版物产量最高的国家，其次是中国和德国。6月，C.H.发表的论文被引用次数最多，而Maude S.L.在共被引作者中排名第一。基于car的治疗研究热点包括多发性骨髓瘤、安全性和毒性、实体肿瘤、car - T细胞以外的免疫细胞工程、基因编辑等。基于car的免疫疗法对癌症患者来说是一种很有前景的治疗方法，并且有一种新兴的趋势是使用先进的基因修饰技术来克服治疗挑战，特别是在实体肿瘤中，并产生更安全，更有效的通用car工程细胞产品。
Chimeric antigen receptor (CAR)-based immunotherapy has shown great potential for the treatment of both hematopoietic malignancies and solid tumors. Nevertheless, multiple obstacles still block the development of CAR-based immunotherapy in the clinical setting. In this study, we aimed to summarize the research landscape and highlight the front lines and trends of this field. Literature published from 2001 to 2021 was searched in the Web of Science Core Collection database. Full records and cited references of all the documents were extracted and screened. Bibliometric analysis and visualization were conducted using CiteSpace, Microsoft Excel 2019, VOSviewer and R software. A total of 5981 articles and reviews were included. The publication and citation results exhibited increasing trends in the last 20 years. Frontiers in Immunology and Blood were the most productive and most co-cited journals, respectively. The United States was the country with the most productive organizations and publications in the comprehensive worldwide cooperation network, followed by China and Germany. June, C.H. published the most papers with the most citations, while Maude, S.L. ranked first among the co-cited authors. The hotspots in CAR-based therapy research were multiple myeloma, safety and toxicity, solid tumors, CAR-engineered immune cells beyond T cells, and gene editing. CAR-based immunotherapy is a promising treatment for cancer patients, and there is an emerging movement toward using advanced gene modification technologies to overcome therapeutic challenges, especially in solid tumors, and to generate safer and more effective universal CAR-engineered cell products.